Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Elena Ciabatti
Polycomb Genes Are Associated With Response to Imatinib in Chronic Myeloid Leukemia
Epigenomics
Cancer Research
Genetics
Minimal Residual Disease (Mrd) in Non‐hodgkin Lymphomas: Inter‐laboratory Reproducibility on Marrow Samples With Very Low Levels of Disease Within the Fil (Fondazione Italiana Linfomi) MRD Network
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Related publications
Micro-Rna Response to Imatinib Mesylate in Patients With Chronic Myeloid Leukemia
Haematologica
Hematology
Treatment Options for Patients With Chronic Myeloid Leukemia Who Are Resistant to or Unable to Tolerate Imatinib
Clinical Therapeutics
Pharmacology
Functional Activity of Cd34-Positive Cells in Chronic Myeloid Leukemia Patients With Different Response to Imatinib Therapy
Experimental Oncology
Cancer Research
Oncology
Prognostic Factors Associated With a Stable MR4.5 Achievement in Chronic Myeloid Leukemia Patients Treated With Imatinib
Oncotarget
Oncology
Imatinib and Plasmacytoid Dendritic Cell Function in Patients With Chronic Myeloid Leukemia
Blood
Biochemistry
Immunology
Cell Biology
Hematology
Dasatinib in the Treatment of Imatinib Refractory Chronic Myeloid Leukemia
Biologics: Targets and Therapy
Oncology
Immunology
Gastroenterology
Pharmacology
Rheumatology
Allergy
The BCL2L11 Deletion Polymorphism Is Not Associated With Imatinib Resistance in Chronic Myeloid Leukemia Patients: Meta Analysis
Oncotarget
Oncology
Epstein-Barr Virus-Associated Lymphoproliferative Disease During Imatinib Mesylate Treatment for Chronic Myeloid Leukemia
Haematologica
Hematology
Somatic Mutations Identified at Diagnosis by Exome Sequencing Can Predict Response to Imatinib in Chronic Phase Chronic Myeloid Leukemia Patients
American Journal of Hematology
Hematology
